The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Dr. Anna Sureda | EBMT 2018 | Summary of the transplant algorithm in Hodgkin lymphoma

Mar 19, 2018

44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Anna Sureda
Catalan Institute of Oncology, Barcelona, ES

  • Dr Sureda gives a summary of the transplant algorithm in lymphoma highlighting that autologous stem cell transplant (ASCT) is still a standard of care in relapsed / refractory Hodgkin lymphoma.
  • She explains that the results of ASCT have been improved by PET-adapted strategies. New drugs such as brentuximab vedotin and checkpoint inhibitors can improve disease status before transplant.
  • Finally, she notes that allogeneic transplant is an option for those who relapse after ASCT but this will become less frequent as new drugs are more successful.

Dr. Anna Sureda | EBMT 2018 | Summary of the transplant algorithm in Hodgkin lymphoma